Raymond James & Associates Arvinas, Inc. Transaction History

Raymond James & Associates

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$41.87 - $57.99 $7,201 - $9,974	-172 Reduced 2.58%	6,491 $289,000
Q2 2022 Aug 12, 2022	SELL	$36.01 - $74.24 $828 - $1,707	-23 Reduced 0.34%	6,663 $280,000
Q1 2022 May 11, 2022	BUY	$60.27 - $81.57 $70,636 - $95,600	1,172 Added 21.25%	6,686 $450,000
Q4 2021 Feb 08, 2022	SELL	$65.85 - $96.21 $69,932 - $102,175	-1,062 Reduced 16.15%	5,514 $453,000
Q3 2021 Nov 02, 2021	SELL	$73.2 - $107.87 $18,519 - $27,291	-253 Reduced 3.7%	6,576 $540,000
Q2 2021 Aug 11, 2021	SELL	$60.45 - $84.26 $1,571 - $2,190	-26 Reduced 0.38%	6,829 $526,000
Q1 2021 May 14, 2021	BUY	$58.19 - $91.37 $398,892 - $626,341	6,855 New	6,855 $453,000

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $986M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.